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Abstract In Alzheimer’s disease (AD), lipid alterations
are present early during disease progression. As some of
these alterations point towards a peroxisomal dysfunction,
we investigated peroxisomes in human postmortem brains
obtained from the cohort-based, longitudinal Vienna-
Transdanube Aging (VITA) study. Based on the neuro-
pathological Braak staging for AD on one hemisphere, the
patients were grouped into three cohorts of increasing
severity (stages I–II, III–IV, and V–VI, respectively). Lipid
analyses of cortical regions from the other hemisphere
revealed accumulation of C22:0 and very long-chain fatty
acids (VLCFA, C24:0 and C26:0), all substrates for per-
oxisomal b-oxidation, in cases with stages V–VI pathology
compared with those modestly affected (stages I–II).
Conversely, the level of plasmalogens, which need intact
peroxisomes for their biosynthesis, was decreased in
severely affected tissues, in agreement with a peroxisomal
dysfunction. In addition, the peroxisomal volume density
was increased in the soma of neurons in gyrus frontalis at
advanced AD stages. Confocal laser microscopy demon-
strated a loss of peroxisomes in neuronal processes with
abnormally phosphorylated tau protein, implicating
impaired trafﬁcking as the cause of altered peroxisomal
distribution. Besides the original Braak staging, the study
design allowed a direct correlation between the biochem-
ical ﬁndings and the amount of neuroﬁbrillary tangles
(NFT) and neuritic plaques, quantiﬁed in adjacent tissue
sections. Interestingly, the decrease in plasmalogens and
the increase in VLCFA and peroxisomal volume density in
neuronal somata all showed a stronger association with
NFT than with neuritic plaques. These results indicate
substantial peroxisome-related alterations in AD, which
may contribute to the progression of AD pathology.
Keywords Aging  Neuroﬁbrillary tangles  Peroxisome 
Plasmalogen  VLCFA
Introduction
Owing to the increased life expectancy, the number of
aging individuals affected by Alzheimer’s disease (AD)
is growing rapidly. Fundamental knowledge has been
generated from basic research and familial mutations
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DOI 10.1007/s00401-011-0836-9highlighting the role of amyloid precursor protein (APP),
presenilin-1 and presenilin-2, as well as pathological
phosphorylation of tau in the neuropathological changes.
However, only limited information is available on initial
events and disease modulators. So far, the e4 allele of
apolipoprotein E (APOE) is the best established genetic
risk factor for sporadic AD [4, 39]. Although neuroﬁ-
brillary degeneration may appear early in life [9], aging
is one major factor for the development of AD-related
neuropathology. The onset and progression of neuro-
pathological alterations (and ﬁnally conversion from mild
cognitive impairment to clinical AD) is variable. Age-
based metabolic changes may lead to an imbalance of
metabolites and/or second messengers promoting mito-
chondrial, endosomal–lysosomal and peroxisomal
dysfunctions, which might be involved in the initiation
of neuropathological events in AD [26, 32]. Mitochon-
dria contribute to aging, as mutations accumulate in the
mitochondrial DNA, leading to dysfunction and net
production of reactive oxygen species (ROS), reviewed
in [26]. The observation that the life span of mice is
extended when catalase, normally localized to the cytosol
and to peroxisomes, is transgenically targeted to mito-
chondria supports the theory of organellar contribution to
aging [37].
Peroxisomes are present in all nucleated human cells,
including all cell types of the brain, and perform anabolic
and catabolic functions and play a major role in generation
and decomposition of ROS, reviewed in [1, 6, 36, 41]. An
altered intra-peroxisomal balance between ROS production
by many oxidases and scavenging of ROS possibly adds to
oxidative stress in AD, as recently suggested from animal
studies [11]. In addition, peroxisomes are required for some
steps in the synthesis of several lipids with antioxidant
properties and are thus involved in the cellular protection
against ROS burden; prominent representatives are plas-
malogens [24] and docosahexaenoic acid (DHA) [10]. The
levels of both of these lipids are decreased in brains of
patients suffering from a generalized peroxisome biogen-
esis deﬁciency (Zellweger syndrome spectrum) [30] and in
AD [15, 18, 19, 29, 34].
Plasmalogens represent a heterogeneous class of phos-
pholipids characterized by a vinyl ether substitution at the
sn-1 position of the glycerol backbone. This glycerol–vinyl
ether bond can only be synthesized in peroxisomes by the
enzymes dihydroxyacetone phosphate acyltransferase
(DHAPAT) and alkyldihydroxyacetone phosphate synthase
(ADHAPS). In brain, ethanolamine is the predominant
head group of plasmalogens. Although in human gray
matter and neurons, the sn-2 position of plasmalogens is
predominantly occupied by polyunsaturated acyl chains,
such as arachidonic acid and DHA, in white matter almost
exclusively monounsaturated acyl chains are present [17].
Plasmalogens were described to be signiﬁcantly reduced in
both gray and white matter of AD patients [15, 18, 19, 34].
The decrease in plasmalogens is independent of the APOE
e4 allele [34]. Moreover, the level of circulating ethanol-
amine–plasmalogens is signiﬁcantly decreased in serum
from clinically and pathologically diagnosed AD subjects
at all stages of dementia, and the severity of this decrease
correlated with the severity of dementia [16, 42].
The polyunsaturated fatty acid (PUFA) DHA (22:6 x3)
is predominantly derived from the diet but can also be
synthesized by glial and endothelial cells via elongation,
desaturation and a ﬁnal step of peroxisomal b-oxidation
from the precursors eicosapentaenoic acid (20:5 x3) or
linolenic acid (18:3 x3). DHA incorporated into phos-
pholipids and cholesterol esters were found to be reduced
in brain [29] and plasma [12] of AD patients and several
studies indicate a decreased risk for AD after an x3 (in
particular DHA) rich diet [3, 20, 31].
The reduced plasmalogen level and increased ROS
production in AD resemble ﬁndings observed in peroxi-
somal disorders. In case of a generalized peroxisome
deﬁciency, such as in patients affected by Zellweger
spectrum disorder (ZSD), the loss of peroxisomal functions
such as plasmalogen biosynthesis and fatty acid a and
b-oxidation leads to decreased amounts of plasmalogens
and bile acids, whereas very long-chain fatty acids
(VLCFA), long-chain dicarboxylic acids and, dependent on
dairy product intake, pristanic and phytanic acid accumu-
late [41]. A decrease in peroxisomal scavenging enzymes,
such as catalase and peroxiredoxins, reviewed in [36],
during aging may lead to peroxisomal ROS imbalance and
consequently to an increase in free radicals and cellular
oxidative stress.
The similarities in lipid alterations observed in AD and
peroxisomal disorders, prompted us to speciﬁcally inves-
tigate the role of peroxisomes in human AD. To this end,
we combined neuropathological, biochemical, lipidomic
and immunohistochemical analyses focusing on peroxi-
somes in well-deﬁned autopsy material derived from the
Vienna Transdanube Aging (VITA) study, a longitudinal,
community-based cohort study [14], enabling us to gener-
ate a uniform sample set of age-matched AD and control
cases. Our results show accumulation of VLCFA and
decreased plasmalogen levels indicating peroxisomal dys-
function in AD, as well as an increase in peroxisomal
volume density in neuronal cell bodies of cortical regions,
all correlating with increasing progression of AD
pathology.
Materials and methods
All analyses were performed in a blinded manner.
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123Immunohistochemistry
Brain sections were formalin-ﬁxed and parafﬁn-embedded.
Bielschowsky–Hirano’s silver staining was used for quan-
tiﬁcation of neuritic plaques. Mouse monoclonal antibody
AT8 (Pierce Biotechnology) was used to detect phos-
phorylated tau protein for quantiﬁcation of NFT.
Quantiﬁcation of pathological markers for AD on brain
sections
For quantitative light microscopic immunohistochemical
analyses, 109 ocular magniﬁcation, 409 objective mag-
niﬁcation and 1-mm
2 grid size were used as microscope
settings. Cortical areas with concentrated pathological
markers were quantiﬁed to deﬁne the number of plaques or
tangles in each grid area; ten grids were counted in each
section. The staging of AD-related neuropathology was
done on the left brain hemisphere according to Braak and
Braak [7, 8]. The quantiﬁcation of neuropathological
markers in parasubiculum, trans-entorhinal cortex, gyrus
frontalis medius, gyrus precentralis and cerebellar cortex of
formalin-ﬁxed and parafﬁn-embedded tissue adjacent to
the snap-frozen tissues used for lipid analysis was done on
the right hemisphere of each brain.
Quantitative Western blot analysis
Snap frozen postmortem tissues from different cortical
brain regions were homogenized in Potter–Elvehjem tissue
grinders at 4C in the presence of protease inhibitor
cocktail (Roche). After measurement of protein concen-
tration, aliquots were stored at -80C until use for
lipidomic or western blot analyses. Homogenized human
brain samples (2 lg of total protein) were diluted in H2O,
heated with sample buffer for western blots [25] and loaded
on precast 10–20% gradient polyacrylamide/Tris–Tricine
gels (VarioGels
, Anamed Elektrophorese). After blot
transfer to PVDF membrane, the samples were probed by
an antibody mixture of b-tubulin (polyclonal rabbit anti-
human b-tubulin III; Sigma) and myelin basic protein
(MBP) (monoclonal rat anti-bovine MBP; Abcam). The
membrane was blocked at room temperature (RT) for 1 h
using 3% bovine serum albumin (Sigma) in PBST (PBS
with 0.05% Tween) before incubating with primary anti-
body (diluted in PBS with 3% BSA) at 4C overnight.
After washing carefully in PBST, the membrane was
incubated with Alexa Fluor 680 goat anti-rat and anti-
rabbit secondary antibodies at RT in the dark for 1 h, and
ﬁnally scanned for quantiﬁcation of the ﬂuorescence signal
intensity using the Odyssey
 infrared imaging system (LI-
COR Biotechnology). MBP, an oligodendrocyte marker,
was used to quantify the amount of myelin in grey matter
samples. To this end, 20, 50 and 80 ng of puriﬁed human
MBP of 18.3 kDa (Hytest) was loaded onto each gel as a
mass standard for quantiﬁcation of the relative amount of
MBP in the human brain tissue samples. The monoclonal
rat anti-bovine MBP antibody (Abcam) targets the bovine
epitope amino acid 82–87 (DENPVV), which is identical in
human MBP isoform 5 (18.5 kDa) and 6 (17.2 kDa). Iso-
form 5 is the most abundant form in the adult human CNS
[33]; isoform 6 is identical to isoform 5 except for an 11
amino acid deletion near the C-terminus [21]. Isoforms 5
and 6 were used for MBP quantiﬁcation. b-Tubulin III was
used as a control for equal loading and transfer. Alexa
Fluor 680-conjugated secondary antibodies were used for
detection with the Odyssey
 infrared imaging system (LI-
COR Biotechnology).
Lipid analysis
VLCFA, pristanic acid and phytanic acid were measured
according to previously described methods [40] and plas-
malogens and PUFA as described in [13]. For improved
method for analysis of plasmalogen subspecies, lipid
standards dissolved in chloroform/methanol (1:2, vol/vol)
were added to the extraction solvent before neutral lipid
extraction, which was performed according to the method
of Bligh and Dyer [5]. Dried lipids were dissolved in
methanol containing 10 mM ammonium acetate. Mass
spectrometry analyses and lipid quantiﬁcations were done
on a triple quadrupole instrument (QUATTRO II from
Micromass) equipped with a nano-ESI source as described
[27].
Peroxisome volume density measurement
Brain sections from gyrus frontalis of ten AD patients each
representing Braak stage III–IV and V–VI, respectively,
and ten controls (Braak stage I–II) as deﬁned (see above)
were immunostained using a polyclonal rabbit anti-PMP70
antibody (Bioreagent) and DAKO EnVision
 detection kit,
peroxidase/DAB, rabbit/mouse (Dako, Glostrup, Denmark)
was used to visualize peroxisomes for light microscopy.
The stained slides were scanned (Hamamatsu, NanoZoo-
mer Digital Pathology) and 15 subareas were randomly
chosen for photographic documentation. At least 24 large,
round neurons with the cytosol surrounding the nucleus and
both nucleus and nucleoli visible were selected for each of
30 individuals; in total, 857 neurons were analyzed. We
optically dissected the nucleus of neurons using the ‘lasso’
function of Adobe Photoshop with white background.
Applying similar tolerance level of ‘magic wand’, we
selected a brown immunoreactive dot representing PMP70
immunopositivity. Using black background, we cut this
selection. Thus, only black cytoplasmic dots from each
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123neuron were present. This was followed by selecting the
cytoplasmic area of the same neuronal images and cutting
with black background creating a black colored image of
the neuronal cytoplasmic area. To determine the density of
black dots per unit cytoplasmic area, we used the black and
white images and the command ‘phase analysis’ using the
software analySIS
 with similar threshold values. The ratio
of black pixels representing PMP70 immunoreactivity to
the cytoplasmic area was used as a measure of peroxisome
density in the neurons. This method is also described in
[23].
Statistical evaluation
Continuous variables are presented as mean and range if
normal distribution can be assumed and as median and
range otherwise. In the case of normally (log-normally)
distributed variables the bars in bar charts represent means
(geometric means) and the error bars represent standard
errors (standard errors calculated on the log-scale and
back-transformed asymmetrically to the original scale).
ANOVA models were used to compare various variables
between stages or NFT or plaque status. Post hoc tests for
pairwise stage comparisons were adjusted for multiple
testing using Tukey’s method. If data on all brain areas
were investigated, areas entered the model as second factor
and the interaction of stage and area was tested. To esti-
mate and test the NFT effect for different degrees of
saturation of fatty acids across plasmalogen species, a
mixed model was employed with a random patient effect
(with compound symmetry correlation pattern), a species
factor nested in the fatty acid type and an interaction term
for tangles and fatty acid type. Similarly, a mixed model
with random patient effect (with compound symmetry
correlation pattern) was used to test for an NFT or plaque
effect with respect to peroxisome density. To compare the
effect of NFT with that of plaques resampling-based
p values were calculated from 10,000 bootstrap samples.
Standard errors presented in bar charts corresponding to
these models are estimated from the mixed models and
thus take account of within-patient correlations. Except for
Tukey’s correction in the context of pairwise post hoc tests
in ANOVA models, no further correction for multiple
testing has been done due to the exploratory character of
the study. All reported p values are the results of two-sided
tests. p B 0.05 was considered to be statistically signiﬁ-
cant. All computations were performed using SAS
software version 9.2 (SAS Institute Inc., Cary, NC, USA,
2008).
Results
Study design and neuropathological staging
Autopsy brain tissues were obtained from 79 individuals
deceased at 80–82 years of age, who had been enrolled in
the VITA study at the age of 75 years, at that time lacking
clinical evidence of dementia. According to neuropatho-
logical investigations of the left brain hemisphere, subjects
with ﬁndings of a-synucleinopathy, including Parkinson’s
disease or Lewy body dementia, frontotemporal lobar
degeneration with TDP-43 proteinopathy, and primary
tauopathies (e.g. corticobasal degeneration), progressive
supranuclear palsy or argyrophilic grain disease were
excluded from the present study. AD-related pathological
alterations in cases involved in our study were staged
according to Braak and Braak [7, 8] using silver staining
and immunohistochemistry with antibodies against phos-
phorylated tau for detection of neuritic plaques and NFT,
respectively and grouped into three categories: Braak stage
I–II, stage III–IV and stage V–VI, with ten patients/group
(Table 1).
From the right hemisphere of each brain, tissue samples
were micro-dissected from the parasubiculum, trans-en-
torhinal cortex, gyrus frontalis medius, gyrus precentralis
and the cerebellar cortex and snap frozen for biochemical
studies. Adjacent tissues were formalin-ﬁxed and parafﬁn-
embedded for histological studies; the results for each tis-
sue and patient are given in Table 2. The observed results
are in good agreement with the original neuropathological
Braak staging performed on the other brain hemisphere.
Some individuals in the group Braak I–II (representing
normal aging/mildly affected cases) showed unexpectedly
high numbers of neuritic plaques (patients 5, 7 and 10 in
Table 2) and NFT (patient 10 in Table 2) in both parasu-
biculum and trans-entorhinal cortex, but were still within
the distribution and range of Braak stage I–II.
Table 1 Characteristics of brain tissues included in the study
Groups B&B Gender Age at death (years) PMI (h)
B&B I–II 4 B&B I, 6 B&B II 10 (5M ? 5F) 81.23 (80.68–82.19) 33.0 (6–95)
B&B III–IV 9 B&B III, 1 B&B IV 10 (2M ? 8F) 81.26 (80.38–82.08) 27.5 (4–44)
B&B V–VI 3 B&B V, 7 B&B VI 10 (2M ? 8F) 81.40 (80.42–82.08) 30.5 (9–85)
PMI post mortem interval
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123The amount of myelin differs between cortical regions
but not with AD pathology
Owing to differing amounts of myelinated ﬁbers in various
cortical areas and because the selective loss of neurons in
AD could alter the relative proportions of lipids across the
samples, we determined the amount of myelin basic protein
(MBP) as a marker for myelin in each tissue sample by
quantitative western blot analysis (Fig. S1). In all cortical
tissues, the amount of MBP was at least sevenfold lower
than the mean value of the white matter controls. There
were signiﬁcant differences in MBP content between
cortical areas (p\0.001), but not between groups of dif-
ferent AD stages within the same brain region (p = 0.630)
(Fig. S1). The lowest amount of MBP was found in the
cerebellar cortex. Among the regions of cerebral cortex,
gyrus precentralis showed the highest amount of MBP (Fig.
S1).
VLCFA accumulate in the brain of AD patients
In mammals, VLCFA with a carbon chain of more than 22
C atoms (and possibly also C22:0) are exclusively degra-
ded by the peroxisomal b-oxidation system [41]. Thus,
Table 2 Quantiﬁcation of neuritic plaques and neuroﬁbrillary tangles in brain tissues
Patient Braak stage Parasubiculum Trans-entorhinal Cortex Gyrus frontalis Gyrus precentralis
NFT Plaque NFT Plaque NFT Plaque NFT Plaque
Braak stage I–II
a
1I I 10 3 0 0 0 0 0
2I I 14 9 0 0 0 0 0
3 I 7 1 20 9 0 0 0 0
4 I–II 3 0 17 0 0 0 0 0
5 II 0 47 3 40 0 54 0 43
6I I 20 4 0 0 0 0 0
7 I 0 31 8 44 0 21 0 6
8 I 2 0 39 0 0 0 0 0
9I I 00 4 0 0 0 0 0
10 II 24 29 62 20 0 15 0 7
Braak stage III–IV
a
11 III–IV 4 0 11 0 0 0 0 0
12 III 1 0 29 0 0 0 0 0
13 III 13 53 11 64 0 49 0 53
14 III 85 3 70 0 0 0 0 0
15 III 0 69 5 58 0 89 0 7
16 III 66 0 108 0 0 0 0 0
17 III 3 0 7 0 0 0 0 0
18 III 19 0 39 0 0 0 0 0
19 III 17 0 42 0 0 22 0 38
20 III 32 65 38 83 0 85 0 71
Braak stage V–VI
a
21 VI 30 11 69 44 8 61 4 5
22 VI 59 37 74 94 24 62 20 39
23 VI 93 71 63 70 19 92 20 61
24 VI 44 14 89 34 8 57 12 59
25 V 77 26 126 32 39 43 57 60
26 VI 14 15 21 39 5 13 0 7
27 V 36 67 95 91 0 143 3 98
28 V 3 4 48 44 8 76 0 37
29 VI 79 89 177 105 87 157 72 91
30 VI 51 7 71 19 2 8 1 8
a Staging of AD neuropathology was according to Braak and Braak [7, 8]
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123hypothesizing multifaceted peroxisomal dysfunctions in
AD, using coupled gas chromatography–mass spectrometry
(GC–MS) we measured the amount of long- and very long-
chain fatty acids in all ﬁve sampled cortical brain regions
of the 30 cases. In contrast to C16:0 and C18:0 (Fig. 1a,
upper two panels), which are mainly degraded in mito-
chondria, C22:0 as well as the VLCFAs C24:0 and C26:0
were increased in all cortical areas except parasubiculum of
the group with the highest Braak score (Fig. 1a, dashed
line, lower three panels). In gyrus frontalis medius, the
observed increase in the individual levels of C22:0, C24:0
and C26:0, and combined C24:0 plus C26:0 (VLCFA),
showed a statistically signiﬁcant difference when Braak
stage I–II were compared with stage V–VI (Fig. 1a, b).
In addition to fatty acid b-oxidation, peroxisomes also
contain the enzymes for a-oxidation of branched-chain
fatty acids, such as phytanic acid. Therefore, we investi-
gated the levels of phytanic acid and pristanic acid (the
product of peroxisomal a-oxidation of phytanic acid) in
the brain samples of our cohort. It should be noted that
the human body does not synthesize phytanic acid; instead,
it is solely derived from dietary intake and, hence, the
amount of phytanic acid was highly variable. Pristanic
acid, the product of peroxisomal phytanic acid a-oxidation,
was only detectable in 38 out of 150 samples, probably due
to dietary habits in this collective of elderly and the results
were not further statistically evaluated.
Increase in VLCFA levels is associated with NFT rather
than with neuritic plaques
Next, we asked whether the observed increase in VLCFA
could be correlated with the amount of neuritic plaques
and/or NFT. As we had quantiﬁed the number of neuritic
plaques and NFT in tissue samples immediately adjacent to
those collected for lipid analyses (Table 2), we regrouped
the 30 patients into cohorts with absence or presence of
NFT and plaques, respectively. For detailed quantitative
and statistical comparisons, we focused on gyrus frontalis
because this region showed the most pronounced difference
in VLCFA levels between AD stages, it is a relatively
mildly affected brain area and, thus, sufﬁcient numbers of
cases with and without the respective pathology were
available for each category (Fig. 1c, d). We never observed
isolated tauopathy (NFT) in the absence of amyloid pla-
ques in our samples. Eight cases had an abundant plaque
load in the absence of tangles, 9 featured both NFT and
plaques and 13 (from 12 of these fatty acid proﬁles could
be obtained) showed neither type of pathology in this brain
region. For one sample, no fatty acid proﬁle could be
obtained. In samples with tangles and plaques, the amount
of C22:0 was signiﬁcantly increased when compared with
those lacking the respective pathology (Fig. 1c; p = 0.013
and p = 0.030, respectively). The analysis of VLCFA
(C24:0 plus C26:0) showed elevated levels that were
associated with both types of pathology and disclosed a
stronger, statistically signiﬁcant (p = 0.003), increase in
the presence of NFT than of neuritic plaques (p = 0.165)
(Fig. 1d). The difference in the extent of elevation of
VLCFA between the two groups of pathology was statis-
tically signiﬁcant (p = 0.024).
The levels of C22:0 and VLCFA show similar trends
of increase in cerebellar cortex of AD brains
When considering whether the increase in VLCFA could
be a direct consequence of abnormally phosphorylated tau,
we compared the amount of VLCFA in the cerebellar
cortex, where tangles are absent, with the cases grouped
according to NFT pathology of gyrus frontalis. Although
the increase was not statistically signiﬁcant, there was a
trend with the mean value of C22:0 increased by 14.5%
(p = 0.336) and of VLCFA (C24:0 and C26:0 combined)
by 36.6% (p = 0.109) in cerebellar cortex of patients with
NFT in the gyrus frontalis (Fig. S2).
Reduced plasmalogen levels in gyrus frontalis of AD
patients were associated with NFT rather
than with neuritic plaques
WhereasVLCFAaredegradedinperoxisomes,thesynthesis
of plasmalogens requires intact peroxisomes. The initial
steps of ether-linked glycerophospholipid biosynthesis
are exclusively carried out by the peroxisomal enzymes
DHAPAT and ADHAPS. Thus, generalized peroxisomal
dysfunction should affect the level of plasmalogens [41].
Because brain plasmalogens predominantly contain etha-
nolamine as head group, we ﬁrst investigated C16:0 and
C18:0 dimethyl acetals derived from total ethanolamine
plasmalogens. This method did not account for C18:1 and
disregarded the fatty acid present at the sn-2 position
(Fig. 2a). In gyrus frontalis, we observed a statistically sig-
niﬁcant reduction (p = 0.027) of total plasmalogen
concentrationswhenthecontrolgroup(BraakstageI–II)was
compared with the AD group, Braak stage V–VI (Fig. 2b).
Sorting the brain specimens according to type of pathology,
the reduction in plasmalogen levels compared with the
unaffected group was more pronounced in the group with
NFT (p = 0.004) than in the one with plaques only
(p = 0.300) (Fig. 2c). This difference in reduction between
NFT and plaques is statistically signiﬁcant (p = 0.003).
The signiﬁcant reduction in plasmalogens association
with NFT prompted us to evaluate the plasmalogen proﬁle
in gyrus frontalis in more detail. In Fig. 2d, the level of all
plasmalogen species accounting for more than 0.1% of
total phospholipids is indicated. Values are given in percent
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absence of NFT in the gyrus frontalis. Although some of
the minor species were not decreased, most plasmalogen
species, including the four major species: C16:0-22:6,
C18:0-20:4, C18:0-22:4 and C18:0-22:6 (striped in
Fig. 2d) accounting for more than 58% of total
Fig. 1 Accumulation of VLCFA in cortical areas of human brains
associated with progressive AD neuropathology. a The content of
long and very long-chain fatty acids in ﬁve different cortical regions,
indicated below the graphs, was determined by GC–MS (n = 10/
group). Relative amounts of the fatty acids C16:0, C18:0, C22:0,
C24:0 and C26:0 are depicted as ratio to the total fatty acid (TFA)
content (91,000). The mean values of each AD severity group are
connected across brain regions by the line pattern indicated above the
graphs. The AD-related neuropathology was deﬁned according to
Braak staging of the contralateral hemisphere. Tissue abbreviations:
PS parasubiculum, TEC trans-entorhinal cortex, GF gyrus frontalis,
GP gyrus precentralis, CB cerebellar cortex. The mean level of
VLCFA (C24:0 and C26:0 combined) in gyrus frontalis is depicted as
ratio to total fatty acids for the three Braak stage groups (b) and of
C22:0 (c) and VLCFA (d) in relation to NFT and plaques. The
increase in VLCFA in stage V–VI when compared with stage I–II was
statistically signiﬁcant (corr. p = 0.044). When NFT were present,
both C22:0 (c left) and VLCFA (d left) were signiﬁcantly increased
(p = 0.013 and 0.003, respectively). Also when the cases were
grouped according to plaques, the levels of C22:0 (c right) and
VLCFA (d right) were elevated when plaques were present, but to a
lesser extent (p = 0.030 and 0.165, respectively). Thus, the increase
in VLCFA was more strongly associated with NFT than with plaques.
Error bars indicate SEM; *p\0.05 and **p\0.01; corr., corrected
for multiple testing (Tukey’s post hoc test)
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123plasmalogens, were reduced. In myelin, mainly saturated
and mono-unsaturated fatty acids have been found at the
sn-2 position of plasmalogens, whereas in neurons pre-
dominantly PUFAs occupy this position [17]. Interestingly,
whereas plasmalogens containing PUFA at the sn-2 posi-
tion were decreased by 7.7% in tissues with NFT present,
those containing mono-unsaturated or saturated fatty acids
were increased by 6.1% (Fig. 2e). This difference was
statistically signiﬁcant (p = 0.019).
DHA and arachidonic acid are not decreased in AD
brains
In addition to the dietary intake, DHA can be endogenously
synthesized by one round of peroxisomal b-oxidation of the
precursor C24:6 [41]. Neither DHA nor arachidonic acid
levels were signiﬁcantly altered in the different cortical
regions (Fig. S3). However, within the plasmalogen frac-
tions, DHA and arachidonic acid were reduced by 6.9 and
Fig. 2 Plasmalogens are reduced in gyrus frontalis with AD pathol-
ogy. a Schematic structure of plasmalogen. b, c The relative levels of
total ethanolamine plasmalogens (PlsEtn) in gyrus frontalis medius
were determined by GC–MS and expressed as ratio to the total fatty
acid (TFA) content (91,000). Reduced levels were observed when the
samples were grouped either by Braak staging of neuropathology
(b corr. p = 0.027) or by the presence or absence of NFT (c left;
p = 0.004) or plaques (c right; p = 0.300). d Individual plasmalogen
sub-species were determined by nano-ESI–MS and depicted as
percentage of the mean level of the same plasmalogen species in
samples without NFT. The four main species (striped) account
together for 58.5% of total plasmalogen. e The level of plasmalogen
species grouped according to the degree of saturation of the fatty acid
at the sn-2 position and the presence or absence of NFT. The
difference between the 6.1% increase in plasmalogens with saturated
(sat) or monounsaturated (MUFA) fatty acids at sn-2 compared with
the 7.7% decrease in those with polyunsaturated fatty acids (PUFA) is
statistically signiﬁcant (p = 0.019) The number (n) of cases in each
group are indicated below the graphs. Error bars indicate SEM;
*p\0.05 and **p\0.01; corr., corrected for multiple testing
(Tukey’s post hoc test)
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1237.6%, respectively, in gyrus frontalis of the AD group
Braak V–VI when compared with control tissues (Braak I–
II) (Fig. S4a, b).
Peroxisomal density is increased in neuronal somata
of AD brains
Our observations of altered concentrations of VLCFA and
plasmalogens raised the question as to whether other per-
oxisomal attributes are changed in AD neurons. Thus, we
next investigated the distribution of peroxisomes directly,
by a quantitative analysis of peroxisomal density in gyrus
frontalis. To this end, we applied immunohistochemical
detection of the peroxisomal membrane protein PMP70
and determined stained area/cell by a morphometric
method in at least 24 neurons of each case. The results
demonstrated an increased number of neurons with a
higher somatic peroxisomal density in gyrus frontalis of
patients with more pronounced AD pathology (Fig. 3a).
The increase in peroxisomal density showed signiﬁcantly
stronger (p = 0.001) association with the presence of NFT
pathology (p = 0.018) than with amyloid plaques
(p = 0.123) (Fig. 3b).
Peroxisomes are absent in neuronal processes
with phosphorylated Tau
Finally, we investigated whether the increase in peroxi-
somal density in the neuronal somata containing NFT
might be due to impaired transport of peroxisomes to
neuronal processes as observed in cell culture models of
organellar trafﬁcking [28, 38]. By laser confocal micros-
copy, we analyzed double immunolabeling of peroxisomes
co-stained for phosphorylated tau. In the neuronal pro-
cesses lacking phospho-tau immunoreactivity, numerous
PMP70-positive peroxisomes (Fig. 4a) and also superoxide
dismutase 2 (SOD2)-positive mitochondria (Fig. 4b) were
present. In contrast, no peroxisomes could be detected in
neuronal processes, likely representing dendrites, with
phosphorylated tau immunopositivity, corresponding to so-
called pre-tangles (Fig. 4c), while the mitochondrial
staining appeared unchanged (Fig. 4d). In neurons with
Fig. 3 Increased peroxisome
density in the soma of neurons
in gyrus frontalis is associated
with NFT. a The peroxisome
density in the cell body of at
least 24 neurons (each
represented by a circle) in gyrus
frontalis from each of the 30
cases in the cohort was
determined by morphometry
after immunohistochemical
staining for PMP70 and plotted
as pixel/mm
2. The total number
of analyzed neurons/Braak
group is indicated at the bottom
of the panel. b The increase in
mean peroxisome volume
density was statistically
signiﬁcant in tissues containing
NFT (p = 0.018) but not in the
group with plaques only
(p = 0.123). The observation
that the increase was more
strongly associated with NFT
than with plaques was
statistically signiﬁcant
(p = 0.001). The number (n)o f
cases in each group is indicated
below the graphs. Error bars
indicate SEM; *p\0.05
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123fully developed NFT, few peroxisomes or mitochondria
could be detected in the soma but not in the processes
(Fig. 4e, f).
Discussion
Previous reports on reduced levels of plasmalogens in gray
and white matter of AD brain led us to hypothesize that
impaired peroxisomal functions contribute to the progres-
sion of AD. Here, we demonstrate that in addition to
plasmalogens, other peroxisomal parameters such as per-
oxisomal density in neurons and concentration of VLCFA
are altered in tissues with AD-related pathology. Speciﬁ-
cally, we observed a signiﬁcant increase in C22:0, C24:0
and C26:0 in gyrus frontalis of AD patients. These changes
were also found in various other brain areas from indi-
viduals with neuropathologically proven AD, except in
samples of the parasubiculum. The interpretation of this
observation merits caution, however; one possible reason
could be that the cytoarchitecture of the parasubiculum is
different. Particularly there are smaller neurons and cell-
free areas as compared to the trans-entorhinal, frontal, or
precentral cortex, and a smaller amount of neurons than
present in the cerebellar cortex. Interestingly, cerebellum
does not show neuroﬁbrillary degeneration; thus, altera-
tions observed in this region suggest that elevated VLCFA
may either be independent of pathological tau processing,
or a regional difference in metabolic pathways contribute
to the elevation. As VLCFA concentrations are normally
higher in white than in gray matter, the observed elevation
of VLCFA might have been due to differing extent of
myelin in our brain specimens. However, the amount of
MBP, which was determined as a measure of myelin in all
samples, was not signiﬁcantly altered during AD progres-
sion. Thus, the possibility that the observed increase in
VLCFA levels was caused by variable amounts of myelin
could be excluded.
The observed accumulation of VLCFA could result
from either reduced peroxisomal b-oxidation or enhanced
fatty acid elongation. In tissues of patients with the
peroxisomal disorder X-linked adrenoleukodystrophy
(X-ALD), both metabolic pathways contribute to the
accumulation of VLCFA [22]. Although peroxisomal
Fig. 4 Peroxisomes but not mitochondria are absent from neuronal
processes featuring pre-tangles. Representative images of confocal
double-immunoﬂuorescenceusingAT8antibodytodetectphospho-tau
(pre-tangle marker) andeither PMP70-positive peroxisomes (a, c,e)o r
SOD2-positive mitochondria (b, d, f) in entorhinal cortex of an AD
patient with Braak stage IV. a, b In the absence of phosphorylated tau,
numerous peroxisomes (a) and mitochondria (b) are present in the
neuronal processes. When phosphorylated tau is present, peroxisomes
are only visible in the soma (arrow), but not in the neuronal process
(carrowheadspointingupwards),butnormalamountsofmitochondria
are present (d). Note the abundance of peroxisomes in a neighboring
neuron, in which no phospho-tau is detected (c arrowheads pointing
downwards). e, f In neurons ﬁlled with NFT, no peroxisomes and only
sporadic mitochondria were detected in the soma. Size bar 10 lm
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123b-oxidation of C22:0, C24:0 and C26:0 is defective in
X-ALD, only C24:0 and C26:0 accumulate. Thus, it has
been argued that C22:0 fails to accumulate because it is a
better substrate for the activated elongation system. In
contrast to X-ALD, in the AD brains we found elevated
levels of both C22:0 and VLCFA (C24:0 and C26:0),
suggesting that in AD impaired peroxisomal degradation of
VLCFA rather than increased elongation accounts for the
accumulation. To our knowledge, this is the ﬁrst report on
changes of VLCFA or C22:0 levels in AD tissue. This
ﬁnding provides another important piece of knowledge
about the complex lipid alterations observed in brain
regions still showing modest progression of AD-related
neuropathology.
Our ﬁnding of reduced amounts of plasmalogens is in
good agreement with previous results [15, 18, 19, 34]. In
myelin, the sn-2 position of plasmalogens (Fig. 2a) pre-
dominantly contains unsaturated or monounsaturated fatty
acids, whereas in neurons PUFAs such as DHA and ara-
chidonic acid dominate. Thus, it is of particular interest
that in a mildly affected region, gyrus frontalis, of late
stage AD, mainly plasmalogen species that carry PUFAs at
the sn-2 position were reduced. This points to a neuronal
(or possibly astrocytic or microglial) impairment rather
than a myelin-based effect.
Notably, in addition to alterations in VLCFA and plas-
malogens, we observed an increased number of neurons
containing a higher somatic volume density of peroxisomes
in gyrus frontalis with increasing Braak score. The setup of
our study allowed us to correlate our biochemical and
histological ﬁndings to different groups of AD severity,
through the neuropathological staging of the contralateral
brain hemisphere. Although amyloid b plaques represent a
hallmark of AD, NFT pathology is widely considered to
correlate better with disease progression [2, 8]. Accord-
ingly, we observed that all peroxisomal abnormalities
(increase in VLCFA and somatic peroxisomal volume
density and decrease in plasmalogens) were signiﬁcantly
better correlated with the appearance of NFT than with
neuritic plaques also quantiﬁed in the immediately adjacent
cortical regions.
Previous observations in cultured neurons demonstrated
that overexpression of tau inhibits kinesin-dependent trans-
port of peroxisomes in neurites [28, 38]. We hypothesized
that the increase in somatic peroxisome density results from
abnormally phosphorylated tau impairing peroxisome traf-
ﬁcking. By confocal laser microscopy, we demonstrated a
considerably reduced number of peroxisomes in neuronal
processes that contained phosphorylated tau in pre-tangles
(Fig. 4).Incontrast,thenumberofmitochondriaappearedto
be nearly unchanged in the same processes. However, both
peroxisomes and mitochondria almost completely disap-
peared in neuronal processes with fully developed NFT.
Thus, the increase in peroxisomal volume density in neuro-
nal somata might indeed represent an early event in pre-
tangle formation. It has also been reported that peroxisomal
proliferationenhancesoxidativestress[35].Thus,thehigher
abundance of peroxisomes could elevate the oxidative bur-
den,inturncausingageneralizedreductionintheimportand
metabolic activities of peroxisomal matrix proteins and
eventually inducing changes in lipid metabolism and lipid-
related second messenger signaling.
The patient collective of the VITA study offered a rare
opportunity to follow progression of AD-related neuro-
pathological alterations in the context of biochemical and
histological parameters of peroxisomes in a homogenous
and exceptionally age-matched cohort. At 75 years of age,
all participants of the VITA study, which had been
recruited from two districts of Vienna, were free of clinical
signs of dementia; 6–7 years later, in 10 of these subjects,
severe AD-related neuropathological ﬁndings (corre-
sponding to Braak stage V–VI) were detected upon
autopsy. Although statistical signiﬁcance was not reached,
the mean level of VLCFA in the cerebellar cortex, not
affected by amyloid plaques, pre-tangles or neuroﬁbrillary
tangle pathology, and serving as a control tissue in our
study, was found to be increased by 36.6% when compared
with the control group (Braak stage I–II). In line with our
observations, recent reports show reduced levels of plas-
malogens in the serum of AD patients [16], which might
even qualify as a predictive marker [42]. Thus, both the
increase in VLCFA in cerebellar cortex and the decreased
plasmalogen levels in serum of patients support the
hypothesis of a systemic age-dependent reduction in
peroxisomal functions. Among the 79 investigated post-
mortem brain samples of 81–82-year-old subjects, none
were entirely free of neuropathological ﬁndings, such as
NFT or plaques, probably reﬂecting that neuronal oxida-
tive stress increases in all aging brains. Reduced
peroxisomal functions may enhance progression of pre-
tangle formation and further accelerate pathological
processes including mitochondrial damage, alterations in
the endosomal–lysosomal system, ER-stress and ﬁnally
neuronal death.
Restoration of the moderately reduced levels of plas-
malogens by dietary supplementation could well have
beneﬁcial effects and should be considered. However,
additional studies focused on the neuropathological inﬂu-
ence of plasmalogen deﬁciency on AD pathology in model
systems are required. The observed peroxisomal alterations
in AD add an important contribution to our knowledge of
complex mechanisms modulating AD pathology.
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